November 18, 2026
Health news, explained with evidence
LIVE

Experimental Bladder Cancer Treatment Shows Tumor Growth Reduction in Animal Study

🔬 Research 2 min read 👁 4

Researchers at Yonsei University College of Medicine evaluated a modified bacterial treatment in a mouse model, observing reduced tumor growth and prolonged survival.

🔬Research

Key points

  • Evaluated rSmeg-hMIF-hIL-7 in a mouse bladder cancer model
  • Observed reduced tumor growth and longer endpoint-free survival
  • Results are preclinical and require human clinical trials

A team of researchers at Yonsei University College of Medicine in South Korea has evaluated an experimental immunotherapy utilizing a recombinant bacterial strain for bladder cancer. The study tested a recombinant form of Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor-interleukin-7 fusion protein, known as rSmeg-hMIF-hIL-7, in a syngeneic subcutaneous mouse model. Bladder cancer frequently presents challenges in clinical settings due to high rates of recurrence and progression, prompting the search for novel therapeutic strategies.

According to the findings published in Nature Health Sciences, mice treated intraperitoneally with the fusion protein demonstrated reduced tumor growth and extended endpoint-free survival compared to controls. RNA sequencing of tumor tissue identified 116 differentially expressed genes, highlighting immune-related transcriptional differences. However, the authors noted that tissue-collection timing and variable tumor burden limited their ability to directly attribute all transcriptional changes strictly to the treatment. Further exploratory analyses and RT-qPCR validation pointed toward specific gene expression patterns that may share parallels with human bladder cancer characteristics.

As this investigation was conducted in an animal model, the results remain highly preliminary and cannot be directly extrapolated to human patients. Animal studies provide initial pharmacological insights, but extensive clinical trials are required to establish safety, optimal dosing, and efficacy in humans. Readers should always consult qualified medical professionals regarding personal health decisions and cancer care.

What to know: Scientists tested a modified bacterial treatment in mice with bladder cancer, finding slower tumor growth and improved survival metrics, though human clinical validation is still necessary.

Source Nature Health Sciences — nature.com/articles/s41598-026-80452-x ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.